| Nov 19 |
Cardiff Oncology Announces New Patent with Claims for the Use of Onvansertib in Treating KRAS mutated mCRC
|
| Nov 9 |
Cardiff Oncology Third Quarter 2024 Earnings: Beats Expectations
|
| Nov 7 |
Cardiff Oncology Reports Third Quarter 2024 Results and Provides Business Update
|
| Nov 7 |
Cardiff Oncology: Some Data Are In; Here's What You Should Know And Look For Next
|
| Oct 30 |
Cardiff Oncology Announces Journal of Clinical Oncology Publication of Data from Phase 2 Trial in Second-line KRAS Mutant mCRC
|
| Oct 24 |
3 US Penny Stocks With Market Caps Over $40M
|
| Oct 4 |
Cardiff Oncology: Paramount Data Imminent In Huge First-Line mCRC Market
|
| Aug 12 |
Cardiff: Second Half Of 2024 mCRC Data Is Major Inflection Point
|
| Aug 10 |
Cardiff Oncology, Inc. (CRDF) Q2 2024 Earnings Call Transcript
|
| Aug 8 |
Cardiff Oncology GAAP EPS of -$0.26 misses by $0.01, revenue of $0.16M beats by $0.1M
|
